DE60128070D1 - Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors - Google Patents

Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors

Info

Publication number
DE60128070D1
DE60128070D1 DE60128070T DE60128070T DE60128070D1 DE 60128070 D1 DE60128070 D1 DE 60128070D1 DE 60128070 T DE60128070 T DE 60128070T DE 60128070 T DE60128070 T DE 60128070T DE 60128070 D1 DE60128070 D1 DE 60128070D1
Authority
DE
Germany
Prior art keywords
kidney
antigen
dumper
nursed
vaccinated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128070T
Other languages
English (en)
Other versions
DE60128070T2 (de
Inventor
Arie Belldegrun
Cho-Lea Tso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE60128070D1 publication Critical patent/DE60128070D1/de
Application granted granted Critical
Publication of DE60128070T2 publication Critical patent/DE60128070T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60128070T 2000-02-14 2001-02-13 Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors Expired - Lifetime DE60128070T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18242900P 2000-02-14 2000-02-14
US182429P 2000-02-14
US18263600P 2000-02-15 2000-02-15
US182636P 2000-02-15
PCT/US2001/004595 WO2001060317A2 (en) 2000-02-14 2001-02-13 Kidney-specific tumor vaccine directed against kidney tumor antigen g-250

Publications (2)

Publication Number Publication Date
DE60128070D1 true DE60128070D1 (de) 2007-06-06
DE60128070T2 DE60128070T2 (de) 2008-01-10

Family

ID=26878083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128070T Expired - Lifetime DE60128070T2 (de) 2000-02-14 2001-02-13 Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors

Country Status (7)

Country Link
US (5) US7572891B2 (de)
EP (1) EP1255554B1 (de)
AT (1) ATE360430T1 (de)
AU (1) AU2001236967A1 (de)
DE (1) DE60128070T2 (de)
ES (1) ES2286104T3 (de)
WO (1) WO2001060317A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE389712T1 (de) 1997-01-31 2008-04-15 Edward P Cohen Krebs immuntherapie mit semi-allogenen zellen
ATE360430T1 (de) 2000-02-14 2007-05-15 Univ California Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
US6646209B2 (en) * 2001-04-13 2003-11-11 Pelstar, L.L.C. Beam scale with user friendly features
ATE437235T1 (de) * 2002-04-16 2009-08-15 Univ California Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix
AU2003298984A1 (en) * 2002-12-27 2004-08-23 Shenzhen Tsinghua Yuanxing Bio-Pharm Science And Technology Co., Ltd. Method of preparing a vaccine and anti-tumor vaccines
CN1548537B (zh) * 2002-12-27 2010-05-05 深圳市源兴生物医药科技有限公司 疫苗制备方法和抗肿瘤疫苗
US20090214494A1 (en) * 2005-03-29 2009-08-27 The Board Of Trustees Of The University Of Illinoi Cancer Vaccines and Therapeutic Methods
AU2006347606B2 (en) * 2005-09-09 2012-10-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
KR100825984B1 (ko) * 2006-03-24 2008-04-28 가톨릭대학교 산학협력단 조사된 인간 ｂ형 간염 표면 항원을 발현하는 암세포를이용하여 종양을 치료하는 방법 및 상기 암세포를 포함하는종양치료용 약학적 조성물
US20080044378A1 (en) * 2006-05-15 2008-02-21 Introgen Therapeutics, Inc. Methods and Compositions for Protein Production Using Adenoviral Vectors
WO2008080116A2 (en) 2006-12-22 2008-07-03 The Regents Of The University Of California New fusion molecule based on novel taa variant
EP2981284A1 (de) * 2013-04-05 2016-02-10 Kyushu University National University Corporation Dna-impfstoff gegen tumore
AU2018219226A1 (en) 2017-02-07 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
KR20190134631A (ko) 2017-03-01 2019-12-04 제넨테크, 인크. 암의 진단 및 치료 방법
US11779602B2 (en) 2018-01-22 2023-10-10 Endocyte, Inc. Methods of use for CAR T cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972353A (en) * 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
AU2861695A (en) 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein
EP0766741A4 (de) * 1994-07-07 1998-02-25 Immunex Corp Gm-csf enthaltene fusionsproteine und antigene und ihre expression in hefe
US7250291B1 (en) * 1998-08-07 2007-07-31 Dana-Farber Cancer Institute Tumor antigens and uses thereof
ATE360430T1 (de) 2000-02-14 2007-05-15 Univ California Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
JP4905957B2 (ja) 2003-10-16 2012-03-28 インスティトゥート オブ ヴァイロロジー Ｍｎ／ｃａ ｉｘおよび癌予後診断
JP5653299B2 (ja) 2011-06-09 2015-01-14 株式会社ジャパンディスプレイ 液晶表示装置

Also Published As

Publication number Publication date
US10035981B2 (en) 2018-07-31
WO2001060317A2 (en) 2001-08-23
US20180371411A1 (en) 2018-12-27
EP1255554A2 (de) 2002-11-13
US20160376556A1 (en) 2016-12-29
US9409965B2 (en) 2016-08-09
AU2001236967A1 (en) 2001-08-27
US20150010587A1 (en) 2015-01-08
US8741306B2 (en) 2014-06-03
ES2286104T3 (es) 2007-12-01
US20020058041A1 (en) 2002-05-16
US7572891B2 (en) 2009-08-11
WO2001060317A3 (en) 2002-05-02
ATE360430T1 (de) 2007-05-15
EP1255554A4 (de) 2004-12-08
EP1255554B1 (de) 2007-04-25
DE60128070T2 (de) 2008-01-10
US20100129313A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
DE60128070D1 (de) Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
Warren et al. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development
Rosenberg Progress in human tumour immunology and immunotherapy
Berzofsky et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Oosterwijk-Wakka et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study
Behm et al. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation
US11590184B2 (en) Oncolytic rhabdovirus expressing IL12
NO20015073D0 (no) Vaksiner
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
Xiang et al. Promising particle-based vaccines in cancer therapy
Alam et al. DNA vaccines for the treatment of prostate cancer
SI1794190T1 (sl) Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope
ES2826480T3 (es) Métodos para predecir la utilidad de neoantígenos para inmunoterapia
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
Ren et al. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles)
Bashir et al. Immunotherapy regimens for metastatic colorectal carcinomas
Bergman Veterinary oncology immunotherapies
HUP0204216A2 (en) A new use of antibodies as vaccines
Hrouda et al. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer
JP2002531520A5 (de)
Todryk et al. Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity
Anton et al. Cytokines and tumor vaccination
MY162106A (en) Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor.their use in the treatment of cancer.
Aurisicchio et al. Patented cancer vaccines: the promising leads

Legal Events

Date Code Title Description
8364 No opposition during term of opposition